PipelineReview.com4h
InnoCare and KeyMed Jointly Announce the License Agreement with Prolium for CD20xCD3 Bispecific Antibody ICP-B02
BEIJING, China I, 2025 I InnoCare Pharma (HKEX: 09969; SSE: 688428) and KeyMed Biosciences (HKEX: 02162) today announced that the two companies, ...
PipelineReview.com4h
CARsgen’s Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial
SHANGHAI, China I, 2025 I CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...
PipelineReview.com4h
Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe
SHANGHAI, China I January 20, 2025 I Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...
PipelineReview.com12h
Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama
PLANEGG-MARTINSRIED, Germany I, 2025 I Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and its licensing partner Klinge Biopharma GmbH ...
PipelineReview.com3d
Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
BAGSVAERD, Denmark I January 17, 2025 I Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is ...
PipelineReview.com3d
FDA approves Lumakras® (sotorasib) in combination with Vectibix® (panitumumab) for chemorefractory KRAS G12C-mutated metastatic colorectal cancer
Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC ...
PipelineReview.com3d
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
MALVERN, PA, USA I January 16, 2025 I Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...
PipelineReview.com5d
Bayer’s Pharma Growth Strategy Progressing Well as Pipeline Advances
WHIPPANY, NJ, USA I January 14, 2025 I On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with ...
PipelineReview.com5d
Be Bio Announces Closing of $92M Series C Financing and Completes Transition to a Multi-Program, Clinical Stage Company
CAMBRIDGE, MA, USA I January 15, 2025 I Be Biopharma, Inc. (“Be Bio” or “the Company”), a leader in B Cell Medicines (BCMs), today announced the closing of its $92M Series C financing. The round ...
PipelineReview.com5d
Chromatin Bioscience’s synthetic promoter supports EsoBiotec’s ESO-T01 CAR-T therapy as it enters the clinic
EDINBURGH, UK I January 15, 2025 I Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced ...
PipelineReview.com4d
FDA approves Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease, expanding its use to the second major type of inflammatory bowel disease
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year ...